Polymorphisms in the mTOR Gene and Risk of Sporadic Prostate Cancer in an Eastern Chinese Population

• Qiaoxin Li ,

  Contributed equally to this work with: Qiaoxin Li, Chengyuan Gu

  Affiliations Cancer Institute, Fudan University Shanghai Cancer Institute, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Chengyuan Gu ,

  Contributed equally to this work with: Qiaoxin Li, Chengyuan Gu

  Affiliations Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Urology, Fudan University Shanghai Cancer Institute, Shanghai, China

  ⨯
• Yao Zhu,

  Affiliations Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Urology, Fudan University Shanghai Cancer Institute, Shanghai, China

  ⨯
• Mengyun Wang,

  Affiliations Cancer Institute, Fudan University Shanghai Cancer Institute, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Yajun Yang,

  Affiliations Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of life Sciences, Fudan University, Shanghai, China, Fudan-Taizhou Institute of Health Sciences, Taizhou, Jiangsu, China

  ⨯
• Jiucun Wang,

  Affiliations Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of life Sciences, Fudan University, Shanghai, China, Fudan-Taizhou Institute of Health Sciences, Taizhou, Jiangsu, China

  ⨯
• Li Jin,

  Affiliations Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of life Sciences, Fudan University, Shanghai, China, Fudan-Taizhou Institute of Health Sciences, Taizhou, Jiangsu, China

  ⨯
• Mei-Ling Zhu,

  Affiliations Cancer Institute, Fudan University Shanghai Cancer Institute, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Ting-Yan Shi,

  Affiliations Cancer Institute, Fudan University Shanghai Cancer Institute, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Jing He,

  Affiliations Cancer Institute, Fudan University Shanghai Cancer Institute, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Xiaoyan Zhou,

  Affiliations Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Pathology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Ding-wei Ye ,

  * E-mail: dwye.shca@gmail.com (DWY); weiqingyi@yahoo.com (QW)

  Affiliations Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Urology, Fudan University Shanghai Cancer Institute, Shanghai, China

  ⨯
• Qingyi Wei

  * E-mail: dwye.shca@gmail.com (DWY); weiqingyi@yahoo.com (QW)

  Affiliations Cancer Institute, Fudan University Shanghai Cancer Institute, Shanghai, China, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, The United States of America

  ⨯